The New York State Department of Health has granted Bio-Techne a clinical laboratory permit for its liquid biopsy-based ExoDx Prostate IntelliScore test, which helps determine whether patients who have an ambiguous prostate specific antigen test result need a prostate biopsy. The test is now available in all 50 states as a result of the decision.
N.Y. health department OKs Bio-Techne's prostate cancer test
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.